Dutch Medical Device Startup Sold to Medtronic for Undisclosed Amount
Netherlands, Thursday, 19 March 2026.
Netherlands-based Fortimedix Surgical was acquired by medical device giant Medtronic in December 2025, marking the 10th successful exit for Dutch investor BVP’s healthcare portfolio. The startup, which developed articulating surgical instruments using laser technology, will operate as Medtronic Articulating Technologies to advance minimally invasive patient care globally.
Strategic Exit Highlights Dutch Medtech Innovation
This acquisition represents a healthtech innovation focused on medical device manufacturing and surgical instrument development. Fortimedix Surgical originated as a spin-off from Fortimedix Manufacturing BV, described as a global leader in B2B contract production of stents [1]. The company applied its laser technology to develop a range of articulating instruments for use across diverse patient therapies, with product development and manufacturing seamlessly integrated under one roof in a fully equipped R&D and pilot production facility [1]. The deal demonstrates the value creation potential within the Netherlands’ biomedical technology sector, where local startups continue to attract attention from global healthcare technology leaders.
How Fortimedix’s Technology Works
The company’s core innovation centers on laser technology applications for creating articulating surgical instruments designed for minimally invasive procedures [1]. These instruments are engineered to improve patient outcomes by enabling surgeons to perform complex procedures through smaller incisions, reducing recovery time and surgical trauma [GPT]. Following the acquisition in December 2025, Medtronic Articulating Technologies will further develop Fortimedix’s technology to advance less invasive care, with the potential to help millions of patients worldwide [1]. The technology positions itself as a user-friendly alternative that prioritizes ease of use in laparoscopic surgeries, according to market analysis [4].
Medtronic’s Acquisition Strategy Continues
Medtronic has demonstrated consistent acquisition activity, having completed 69 total acquisitions spanning 13 countries, with peak activity occurring in 2015 with 9 acquisitions, 2014 with 7 acquisitions, and 2020 with 6 acquisitions [2]. The company’s acquisition strategy focuses prominently on Cardiac and Vascular Disorders with 19 acquisitions, Orthopedics with 10 acquisitions, and Wearable Technology with 7 acquisitions [2]. Over the past five years from 2020 to 2025, Medtronic averaged 0.8 acquisitions per year, with the Fortimedix deal representing part of this strategic expansion [2]. The medical device giant reported annual revenue of $30 billion in 2022, providing substantial resources for continued acquisitions and technology development [4].
Investment Partners Celebrate Successful Exit
Both BVP and LIOF served as early investors in Fortimedix Surgical, supporting the company’s growth since its founding [1]. Casper Bruens, Partner at BVP, noted that this transaction marks the 10th successful exit within the BVP Health portfolio and underscores their commitment to supporting impactful healthcare innovations that improve patient outcomes [1]. LIOF supported the company’s growth ambitions through financing from various funds, with Siska van Houdt, manager of Participations & Financing at LIOF, expressing pride in the company’s next step under Medtronic ownership [1]. The successful exit validates the Dutch innovation ecosystem’s ability to nurture medtech startups from inception through to acquisition by global industry leaders, demonstrating the strength of Netherlands-based medical technology innovation.